Painless Thyroiditis Presenting as Hypercalcemia in Pregnancy: A Rare Case Report

Homaid Alsahafi, Bandar Damanhuri, Faizal Ahmed, Faisal Almalki, Dhyaa Mokhtar

Department of Endocrinology & Diabetology, Hera General Hospital, Makkah, Saudi Arabia.

ABSTRACT

The evaluation and treatment of pregnant women with thyrotoxicosis parallels that of nonpregnant women and men, but presents some unique problems. Painless thyroiditis is a very rare cause of thyrotoxicosis in pregnancy. In our report we present a case of painless thyroiditis in a 31 years pregnant woman old presenting with hypercalcemia in pregnancy.

Keywords: Painless Thyroiditis, Hypercalcemia, Thyrotoxicosis.

Article History:
Received: 03-11-2016, Revised: 17-11-2016, Accepted: 28-11-2016

INTRODUCTION

Hyperthyroxinemia during pregnancy is relatively uncommon. Approximately 1 or 2 out of 1000 pregnancies will be complicated by hyperthyroidism.1 The major causes of thyrotoxicosis in women of child bearing age is Graves’ disease.2 Painless thyroiditis is a disease causing thyrotoxicosis during the postpartum period.3 It is characterized by transient thyrotoxicosis, followed sometimes by hypothyroidism, and then recovery.4 In our literature search we found only one case of painless thyroiditis presenting in pregnancy and no cases of painless thyroiditis presenting with hypercalcemia in pregnancy.

CASE REPORT

31 year old female Gravida 4 Para 3+0 in her 20th week of gestation presented to Emergency Room (ER) with history of progressive fatigue and vomiting for 14 days. Upon arrival, she was pale, cachectic, conscious, and drowsy with Glasgow coma scale of 13/15. Her vitals were stable with pulse rate of 114 per minute and regular. General and systemic examination was unremarkable.

On day 1, Plane computerized tomography (CT) brain was done in the Emergency room (with precautions) which came back normal. Initial essential blood work showed; Hemoglobin 9.8 mg/dl, Platelet 299, White blood cells 20, serum creatinine 1.8 mg/dl, Urea 74 mg/dl, serum potassium 3.2 mmol/L, serum sodium 132 mmol/L, and the patient was admitted to the intensive care unit for further management.

A full blood work showed: serum calcium 18.8 mg/dl, serum albumin 2.4 mg/dl, serum magnesium 1.6, serum phosphate 4.2, serum chloride 106, serum aspartate transaminase 90, serum alanine transaminase 24, serum alkaline phosphate 2.3, serum bilirubin (total 0.8, Direct 0.7) serum amylase 925, creatinine kinase 25, serum thyroid stimulating hormone (TSH) 0.005, serum free thyroxin (FT4) 394, serum free triiodothyronine (FT3) 21, serum parathyroid hormone (PTH) 77, ethrocytesedematation rate (ESR ) 120, HIV serology negative, and Tumor markers was elevated (carceno embryonic antigen (CEA) 0.7 ng/ml, alpha fetoprotein (AFP) 300IU/ml). So a diagnosis of sever hypercalcemia, severe thyrotoxicosis, and pancreatitis was made. Elevated tumors markers were attributed to placental growth. The patient started on high saline infusion at a rate of 300ml/h, calcitonin 400mg subcutaneous injections Q12H, hydrocortisone 50mg IV Q8H, Carbimazole 10mg PO Q8H, propranolol 10mg PO Q8H, ceftiraxone 1G IV Q12H, metronidazole 500mg IV Q8H, and thiamin 100mg IV Q24H. A blood sample for parathyroid related protein (PTHrp) was sent to specialized centre in Germany.

On Day 2, patient improved clinically, but she remained lethargic. Blood investigations showed serum calcium 17.8, serum potassium 2.7, hemoglobin 7.5, white blood cells 19 and Vitamin D level was 4.5 ng/ml. Same treatment and 1 unit Packed RBCs was given. On Day 3, patient improved significantly, became fully conscious and oriented, sitting without support, and taking oral ly.

Investigation revealed serum calcium 12.3, serum creatinine 1.7, urea 43, serum potassium 3.3, serum magnesium 0.7, serum amylase 381, hemoglobin 8.4, white blood cells 25. Magnesium was replaced and hydrocortisone stopped. On Day 5, serum calcium 9.9, serum potassium 3.4, urea 50. Calcitonin was stopped. On Day 7, serum calcium...
dropped to 7.4, serum creatinine 1.0, urea 26, serum potassium 2.7, Hemoglobin 9. Potassium was corrected, and the patient was shifted to female medical ward (FMW) in good condition. On Day 8, serum calcium 7.2 (low), serum creatinine 1.0, urea 26, serum potassium 3.1, serum magnesium 1.4. The patient discharged home in good condition on oral treatment.

Patient was seen one week later in outpatient clinic with complaints of fatigue and anxiety. Investigation revealed serum calcium of 5.2, serum albumin 2.9, serum potassium 3.2. Oral calcitriol and calcium carbonate. PTHrp (parathyroid related protein) was negative. Upon next outpatient clinic (in the same week); serum calcium 8.2, serum albumin 2.9 serum magnesium 1.6, serum potassium 3.5. Calcitriol and calcium carbonate were continued. Subsequently during next few weeks Carbimazole, calcitroil and calcium tablets were tapered and stopped. Her thyroid function test and calcium were normal. Finally, patient delivered healthy baby girl in good conditions.

**DISCUSSION**

Painless thyroiditis is characterized by transient hyperthyroidism, followed sometimes by hypothyroidism, and then recovery. Synonyms for this disorder include silent thyroiditis, subacute lymphocytic thyroiditis, and lymphocytic thyroiditis with spontaneously resolving hyperthyroidism. Painless thyroiditis accounts for approximately 0.5 to 5 percent of cases of hyperthyroidism. Synonyms for this disorder include silent thyroiditis, subacute lymphocytic thyroiditis, and lymphocytic thyroiditis with spontaneously resolving hyperthyroidism. Painless thyroiditis accounts for approximately 0.5 to 5 percent of cases of hyperthyroidism.**

Factors postulated to initiate painless thyroiditis include excess iodine intake and various cytokines.

Our case presented with hypercalcemia and thyrotoxicosis. As thyroid scintigraphy was not applicable in the pregnant case, we assumed Graves’ disease to be highly probable, because very few cases of painless thyroiditis during pregnancy had been previously reported. For this reason and in view of the severe thyrotoxicosis Carbimazole was started before the TRAb result was available.

Hypercalcemia during pregnancy or after delivery is uncommon, and mostly associated with primary hyperparathyroidism (PHPT). If unrecognized, it may increase maternal and fetal morbidity. Hypercalcemia may also develop in pregnant women due to PTH-related protein (PTHrP)-producing malignant tumors (humoral hypercalcemia of malignancy). Since PTHrP is produced physiologically in fetal and maternal tissues, hypercalcemia may occasionally develop during pregnancy, puerperium, and lactation due to excessive production of PTHrP in the placenta and/or mammary glands. In hyperthyroidism the rate of bone formation and resorption are both accelerated but the bone resorption usually predominates over bone formation. As a result, significantly higher serum calcium level could be found in some hyperthyroid patients, but usually mild (< 10.8 mg/dL). Rarely, the calcium level may be severe enough to cause symptomatic hypercalcemia.

Our case had severe Hypercalcemia. As parathyroid scintigraphy was not possible in pregnancy medical management was initiated for hypercalcemia presuming a diagnosis of concomitant Primary Hyperparathyroidism. After few days of carbimazole therapy patient developed symptomatic hypocalcemia and she was treated with calcium carbonate and calcitriol. After few weeks carbimazole was stopped because patient was euthyroid. Calcium and calcitriol was also tapered and stopped as serum calcium normalized. A diagnosis of Silent thyroiditis was made as thyrotoxicosis was transient. Retrospectively, this patient might not have the true thyroid crisis because hypercalcemia alone can cause all the patients symptoms. Therefore, anti-thyroid medications should not be given to control her hyperthyroidism. Severe hypercalcemia was rarely reported in patients with hyperthyroidism with the highest level of 15.8 mg/dL in the previous literature. The excessively high level of calcium may be further explained by the patient’s marked dehydration from recurrent vomiting. Transient Hypocalcemia during recovery phase in this case could have been due to calcitonin injection and concomitant vitamin d deficiency.

To our knowledge this is the first case report of Silent Thyroiditis presenting with Hypercalcemia in Pregnancy.

**REFERENCES**

1. Morrealo de Escobar G, Obregon MJ, Escobar del Rey F. Is neuropsychological development related to maternal hyperthyroidism or maternal hypothyroxinemia? J Clin Endocrinol Metab, 2000; 85: 3975-3987

**Source of Support:** Nil. **Conflict of Interest:** None Declared.

**Copyright:** © the author(s) and publisher. IJMRP is an official publication of Ibn Sina Academy of Medieval Medicine & Sciences, registered in 2001 under Indian Trusts Act, 1882. This is an open access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.